Opinion/decision on a Paediatric investigation plan (PIP): Erdafitinib, decision type: , therapeutic area: , PIP number: P/0190/2022
Quality data requirements for applications for biological veterinary medicinal products intended for limited markets - Scientific guideline
Opinion/decision on a Paediatric investigation plan (PIP): Sotrastaurin acetate, decision type: , therapeutic area: , PIP number: P/155/2011
Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Multiple Sclerosis, Date of authorisation: 17/03/2011, Revision: 36, Status: Authorised
Draft guideline on clinical investigation of medicinal products in the treatment of depression - Revision 3
EudraVigilance Expert Working Group (EV-EWG) work programme 2023-2024
Opinion/decision on a Paediatric investigation plan (PIP): Finerenone, decision type: , therapeutic area: , PIP number: P/0365/2022
Summary of opinion: Keytruda,pembrolizumab, 14/09/2023, Positive
Opinion/decision on a Paediatric investigation plan (PIP): Stelara,Ustekinumab, decision type: , therapeutic area: , PIP number: P/0401/2022
Opinion/decision on a Paediatric investigation plan (PIP): Cannabidiol,delta-9-tetrahydrocannabinol, decision type: , therapeutic area: , PIP number: P/0373/2022